Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

Abstract:
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today it has been awarded the "Young Talent" Award at the INVESTOR AWARDS 2013, referring to a newly listed company.

NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

Paris, France | Posted on November 8th, 2013

Nanobiotix was judged as the company, outside of the CAC 40, that achieved the most successful and most promising IPO of the year. The Company came first in this category for successfully meeting the main criteria: corporate profile, leadership in its business activity and financial health.

"It is an honor to receive this award from the Investor Awards panel," said Laurent Levy, CEO and co-founder of Nanobiotix. "This award reflects the success of the Nanobiotix IPO in October 2012, where many investors showed an interest in our breakthrough technology in nanomedicine for local cancer treatment. We remain focused on the clinical development of our products, which positions us as a leader in nanomedicine. We are also preparing for the challenges around the marketing of our lead product, NBTXR3, which could occur in 2017."

This prize was awarded by Boursorama and Morningstar that jointly organize the largest survey that selects listed companies by individual and professional investors' preferences.

The online survey was conducted with investors by OpinionWay in May 2013. In total, more than 40,000 votes were collected (two-thirds of individuals and a third of professionals).

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please click here

Contacts:
Nanobiotix

Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)1 53 63 27 27
+33 (0)6 88 20 35 59


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53


College Hill
Media relations (Outside France)
Melanie Toyne Sewell / Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Oxford Instruments’ Triton Cryofree dilution refrigerator selected by Oxford University for developing scalable quantum nanodevices September 2nd, 2015

JEOL Introduces New Best-in-Class Field Emission SEM September 2nd, 2015

TCL and QD Vision Demonstrate the Future of Wide Color Gamut Television at IFA: Color IQ Based Display is the First Commercially-Branded Television to Present Over 90% of ITU Rec. 2020 Color Gamut September 2nd, 2015

Atomic Force Microscopes from Asylum Research Guide the Development of Thin Film Deposition and Etch Processes September 2nd, 2015

Nanomedicine

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Using DNA origami to build nanodevices of the future September 1st, 2015

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Announcements

For 2-D boron, it's all about that base: Rice University theorists show flat boron form would depend on metal substrates September 2nd, 2015

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Phagraphene, a 'relative' of graphene, discovered September 2nd, 2015

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

RUSNANOPRIZE Directorate Announces New Deadline for Nominations Submission – September 11, 2015 September 1st, 2015

$200K Awarded to Develop In Vitro Lung Test for Toxicity of Inhaled Nanomaterials: In Vitro Lung Test Designed to Protect Human Health and Replace Animal Testing September 1st, 2015

Seeing quantum motion August 30th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic